EA201390670A1 - Новый адъювант - Google Patents

Новый адъювант

Info

Publication number
EA201390670A1
EA201390670A1 EA201390670A EA201390670A EA201390670A1 EA 201390670 A1 EA201390670 A1 EA 201390670A1 EA 201390670 A EA201390670 A EA 201390670A EA 201390670 A EA201390670 A EA 201390670A EA 201390670 A1 EA201390670 A1 EA 201390670A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new
adjustent
antigen
combination
relates
Prior art date
Application number
EA201390670A
Other languages
English (en)
Other versions
EA033816B1 (ru
Inventor
Карлос АЛОНСО-БЕДАТЕ
Мануэль СОТО-АЛЬВАРЕС
Нуриа Пароди-Де Ла Фуенте
Яго Пико Де Соаньа-Суарес
Original Assignee
Лабораториос Лети, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лабораториос Лети, С.Л. filed Critical Лабораториос Лети, С.Л.
Publication of EA201390670A1 publication Critical patent/EA201390670A1/ru
Publication of EA033816B1 publication Critical patent/EA033816B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

Изобретение относится к новому адъюванту и к его применению в комбинации с антигеном.
EA201390670A 2010-11-10 2011-11-10 Молекула нуклеиновой кислоты, служащая адъювантом для связанного полинуклеотида, кодирующего антиген EA033816B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41203410P 2010-11-10 2010-11-10
EP10190705 2010-11-10
PCT/EP2011/069849 WO2012062861A1 (en) 2010-11-10 2011-11-10 New adjuvant

Publications (2)

Publication Number Publication Date
EA201390670A1 true EA201390670A1 (ru) 2013-10-30
EA033816B1 EA033816B1 (ru) 2019-11-28

Family

ID=43795122

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390670A EA033816B1 (ru) 2010-11-10 2011-11-10 Молекула нуклеиновой кислоты, служащая адъювантом для связанного полинуклеотида, кодирующего антиген

Country Status (18)

Country Link
US (1) US9187751B2 (ru)
EP (1) EP2638062B1 (ru)
JP (1) JP5986576B2 (ru)
KR (1) KR102010994B1 (ru)
CN (1) CN103270048B (ru)
AR (1) AR083829A1 (ru)
AU (1) AU2011328129B2 (ru)
CA (1) CA2817421C (ru)
CO (1) CO6731076A2 (ru)
EA (1) EA033816B1 (ru)
ES (1) ES2676179T3 (ru)
HU (1) HUE038386T2 (ru)
IL (1) IL226286A0 (ru)
MX (1) MX345739B (ru)
NZ (1) NZ609952A (ru)
PL (1) PL2638062T3 (ru)
SG (1) SG190222A1 (ru)
WO (1) WO2012062861A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015032978B1 (pt) * 2013-07-02 2022-08-16 Institut De Recherche Pour Le Développement Método de diagnóstico para a detecção de anticorpos indicativos de leishmania sul americana e kit de diagnóstico para detecção de anticorpos antileishmaniose

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6458359B1 (en) * 1998-12-23 2002-10-01 C.B.F. Leti S.A. Chimeric gene formed by the dna sequences that encode the antigenic determinants of four proteins of l. infantum and protein encoded by said gene, and pharmacuetical composition useful for preventing and/or treating leishmaniosis in animals or humans
US6525186B2 (en) 1998-12-23 2003-02-25 C.B.F. Leti S.A. Chimeric gene formed of the DNA sequences that encode the antigenic determinants of four proteins of L. infantum, useful of serologic diagnosis of canine leishmaniosis and protein obtained
CA2256124C (en) * 1998-12-23 2015-06-16 C.B.F. Leti S.A. Chimeric gene formed of the dna sequences that encode the antigenic determinants of four proteins of l. infantum, and protein encoded by said gene, and pharmaceutical composition useful for preventing and/or treating leishmaniosis in animals or humans
FR2826018B1 (fr) * 2001-06-18 2005-01-07 Pasteur Institut Tunis Gene associe a la virulence du parasite leishmania
WO2003047602A1 (en) 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
CN101098958A (zh) * 2002-02-21 2008-01-02 免疫医疗疫苗公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途
ES2344698T3 (es) 2003-04-23 2010-09-03 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Vacuna contra la tuberculosis con eficacia mejorada.
KR100992646B1 (ko) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
EP1687023B1 (en) 2003-11-05 2012-10-03 C.B.F. Leti, S.L. Unipersonal Use of specific histones for the treatment of parasitic diseases
RU2521499C2 (ru) 2008-01-18 2014-06-27 Лабораториос Лети, С.Л. Униперсональ ВАКЦИНА, СОДЕРЖАЩАЯ ЭКСТРАКТ РИБОСОМНОГО БЕЛКА (RPE) И Th1- АКТИВИРУЮЩИЙ АДЪЮВАНТ
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي

Also Published As

Publication number Publication date
IL226286A0 (en) 2013-07-31
WO2012062861A1 (en) 2012-05-18
EA033816B1 (ru) 2019-11-28
CA2817421C (en) 2020-04-14
EP2638062A1 (en) 2013-09-18
SG190222A1 (en) 2013-06-28
AU2011328129A1 (en) 2013-05-23
CO6731076A2 (es) 2013-08-15
EP2638062B1 (en) 2018-04-25
HUE038386T2 (hu) 2018-10-29
ES2676179T3 (es) 2018-07-17
JP2014500719A (ja) 2014-01-16
KR102010994B1 (ko) 2019-08-14
CN103270048A (zh) 2013-08-28
US9187751B2 (en) 2015-11-17
NZ609952A (en) 2015-05-29
US20140030293A1 (en) 2014-01-30
PL2638062T3 (pl) 2018-11-30
KR20130121863A (ko) 2013-11-06
CA2817421A1 (en) 2012-05-18
JP5986576B2 (ja) 2016-09-06
AR083829A1 (es) 2013-03-27
CN103270048B (zh) 2016-11-23
AU2011328129B2 (en) 2016-08-11
MX2013005222A (es) 2014-04-07
MX345739B (es) 2017-02-14

Similar Documents

Publication Publication Date Title
LTC2635601I2 (lt) Antikūnai prieš il-23
DK2651436T3 (da) Mycobakterie antigen sammensætning.
UY34456A (es) Anticuerpos anti-il-36r
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
BR112013016235A2 (pt) anticorpo modificado com meia-vida aumentada
CA141065S (en) Dual c clip
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
BR112014009476A2 (pt) refletor, iluminador e uso do iluminador
FI20105110A0 (fi) Refraktometri
CL2011002403S1 (es) Luminaria solar.
DK2538127T3 (da) Gravlanterne
IT1398037B1 (it) Chitarra con manico fissato con mezzi di arresto rapido.
EA201390670A1 (ru) Новый адъювант
IT1397872B1 (it) Dispositivo antisismico.
BR112012033644A2 (pt) tapentadol para uso no tratamento de síndrome do intestino irritável
TR201900608T4 (tr) Bir hava hazırlama cihazına sahip olan davlumbaz cihazı.
UY33207A (es) Métodos de preparación de tiazolidinas
ES1073550Y (es) Mesa promocional
RU2010153530A (ru) Летательный аппарат
TN2010000567A1 (fr) المحطة الكهرمائية الشمسية
TN2010000017A1 (fr) مستحضر تجميلي دوائي
CL2011001069S1 (es) Triciclo.
BR112012025486A2 (pt) peptídeos cluap1 e vacinas incluindo os mesmos
IT1401473B1 (it) Dispositivo di compressione di polveri e simili.
CL2009001549S1 (es) Sillon.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM